Skip to Main content Skip to Navigation
New interface
Journal articles

Nouveaux aspects de la lutte contre la rage

Abstract : Rabies still causes about 60,000 human deaths per year, mainly in poor populations in Africa and Asia. However, since Louis Pasteur developed the first vaccine 130 years ago, prophylactic measures have been considerably improved and simplified. They now consist of the vaccine combined with purified rabies immunoglobulins of equine or human origin. In general, however, post-exposure prophylaxis protocols are long and expensive. Furthermore, the immunoglobulins used for associated serotherapy are costly and not widely available in developing countries. Approaches have been developed to deal with these two issues that offer hope for a paradigm shift for the benefit of exposed populations. Finally, mass rabies vaccination in dogs, which are the most cost-effective measure for preventing rabies in humans, are difficult to implement and sometimes have moderate effectiveness. The identification and analysis of the epidemiological drivers conditioning the circulation of the virus in dog populations allow a better understanding of the key control points that need to be associated with these campaigns for a better efficacy.
Complete list of metadata

Cited literature [76 references]  Display  Hide  Download
Contributor : Guilherme Dias de Melo Connect in order to contact the contributor
Submitted on : Thursday, October 29, 2020 - 11:17:21 AM
Last modification on : Thursday, April 7, 2022 - 10:10:54 AM

Links full text




Hervé Bourhy, Guilherme Dias de Melo, Arnaud Tarantola. Nouveaux aspects de la lutte contre la rage. Bulletin de l'Académie Nationale de Médecine, 2020, ⟨10.1016/j.banm.2020.09.036⟩. ⟨pasteur-02983037⟩



Record views